Inclusive of all taxes
DAPAZIGA-10 Tablet is a cutting-edge oral antidiabetic medication containing 10 mg of Dapagliflozin, a selective Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor designed to manage Type 2 Diabetes Mellitus (T2DM) effectively. By targeting the renal SGLT2 protein, DAPAZIGA-10 reduces glucose reabsorption in the kidneys, thereby facilitating increased urinary glucose excretion independent of insulin pathways. This unique mechanism helps achieve superior glycemic control by lowering HbA1c, fasting, and postprandial blood glucose levels while also offering additional health benefits such as modest weight reduction and systolic blood pressure lowering. Manufactured under strict WHO-GMP compliant standards by BluepillExpress, DAPAZIGA-10 ensures consistent high bioavailability, safety, and patient tolerance, making it an ideal choice for pharmaceutical companies seeking reliable third-party manufacturing and global distribution under the Dr Precision label. Its proven cardio-renal protective effects make it a comprehensive therapeutic option not only to control glucose levels but also to reduce hospitalization risk due to heart failure among T2DM patients with cardiovascular complications. Its once-daily dosing regimen fosters patient adherence and simplifies diabetes management protocols within clinical and hospital settings. Overall, DAPAZIGA-10 combines precision formulation and advanced pharmacological benefits, positioning it as a premium SGLT2 inhibitor tailored for professional pharmaceutical partnerships focused on diabetes care.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Dapagliflozin 10 mg |
| Pharmacological Class | SGLT2 Inhibitor, Antihyperglycemic Agent |
| Mechanism of Action | Selective inhibition of renal SGLT2 protein to promote urinary glucose excretion independent of insulin |
| Indications | Type 2 Diabetes Mellitus management, reduction of heart failure hospitalization risk in T2DM with cardiovascular disease |
| Dosage Form | Oral Tablet |
| Manufacturing Standards | WHO-GMP compliant, manufactured by BluepillExpress |
| Additional Benefits | Weight reduction, systolic blood pressure control, cardio-renal protection |
| Safety Profile | Low risk of hypoglycemia when used alone |
| Dosing Frequency | Once daily |
| Labeling and Packaging | Available for third-party manufacturing and private labeling under Dr Precision brand |
| Attributes | Description |
|---|---|
| Active Substance | Dapagliflozin |
| Strength | 10 mg per tablet |
| Tablet Type | Oral, film-coated tablets |
| Therapeutic Use | Management of Type 2 Diabetes Mellitus (T2DM) |
| Dosage Regimen | Once daily, oral administration |
| Manufacturer | BluepillExpress |
| Certification | WHO-GMP certified manufacturing facility |
| Packaging Options | Suitable for export, third-party manufacturing, and private labeling |
| Country of Origin | India |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
DAPAZIGA-10 not only improves glycemic control but also reduces the risk of hospitalization for heart failure in patients with T2DM and established cardiovascular disease by its cardio-renal protective properties demonstrated in clinical trials.
Yes, because DAPAZIGA-10 acts by inhibiting glucose reabsorption in the kidney independent of insulin secretion or action, it is effective even for insulin-resistant patients.
DAPAZIGA-10 is manufactured under WHO-GMP compliant facilities by BluepillExpress, ensuring high quality, safety, and adherence to international pharmaceutical standards.
Yes, DAPAZIGA-10 is tailor-made for third-party manufacturing, export, and private labeling collaborations with pharmaceutical companies globally.
A once-daily oral dose improves patient adherence and compliance, easing diabetes management and enhancing overall treatment outcomes.
Country Of Origin: India
DAPAZIGA-10 Tablet is an advanced oral antidiabetic medication containing Dapagliflozin 10 mg, a selective SGLT2 inhibitor. It is primarily indicated for the management of Type 2 Diabetes Mellitus (T2DM), helping patients achieve better glycemic control by promoting urinary glucose excretion independent of insulin pathways. Manufactured by BluepillExpress under internationally certified GMP facilities, DAPAZIGA-10 offers high bioavailability, excellent patient tolerance, and strong safety standards—making it ideal for global third-party manufacturing and pharmaceutical distribution partnerships.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
DAPAZIGA-10 Tablet is a state-of-the-art medication developed for the management of Type 2 Diabetes Mellitus (T2DM). It features Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has significantly transformed the landscape of antidiabetic therapy due to its insulin-independent mechanism, cardio-renal protection, and weight-reducing effects.
Dapagliflozin works by selectively inhibiting the SGLT2 protein in the renal proximal tubules, thereby reducing glucose reabsorption in the kidneys and increasing urinary glucose excretion. This not only lowers fasting and postprandial blood glucose levels but also contributes to modest weight loss and reduced systolic blood pressure, making it an excellent choice in the holistic management of diabetic patients.
DAPAZIGA-10 is manufactured under WHO-GMP compliant facilities and is tailored for third-party manufacturing, export, and private labeling under BluepillExpress, India's globally trusted pharmaceutical exporter.
Pharmacological Class
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
Antihyperglycemic Agent
Mechanism of Action
Dapagliflozin selectively inhibits SGLT2 in the kidneys, reducing glucose reabsorption and promoting its elimination via urine. This mechanism is independent of insulin secretion or action, making it beneficial even in insulin-resistant patients.
Indications
Type 2 Diabetes Mellitus (as monotherapy or combination therapy)
To reduce the risk of hospitalization for heart failure in patients with T2DM and established cardiovascular disease
Adjunct to diet and exercise for glycemic control
Key Benefits
Improves Glycemic Control: Effectively lowers HbA1c, fasting blood sugar, and postprandial glucose.
Weight Reduction: Promotes calorie loss through glucosuria, leading to modest weight loss.
Blood Pressure Control: Helps reduce systolic BP without increasing heart rate.
Cardio-Renal Benefits: Clinical trials show reduction in cardiovascular events and protection of kidney function.
Low Risk of Hypoglycemia: As it doesn’t stimulate insulin release, the hypoglycemia risk is minimal when used alone.
Convenient Once-Daily Dose: Promotes better patient adherence and compliance.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
